SK Capital Is Said to Near Deal for Swiss Drug Distributor Swixx
Summarize this article with:
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000US private equity firm SK Capital Partners is nearing a deal to acquire Swiss drug distribution company Swixx Biopharma SA, according to people familiar with the matter. The companies are poised to announce the transaction as soon as Monday, the people said, asking not to be identified as the information is private. A deal could value Swixx at about €1.5 billion ($1.8 billion), some of the people said. SK Capital has secured financing from alternative asset manager Ares, they added.